MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
48.46
-0.29
-0.59%
After Hours: 48.46 0 0.00% 16:10 07/10 EDT
OPEN
48.80
PREV CLOSE
48.75
HIGH
48.80
LOW
47.39
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
59.68
52 WEEK LOW
31.35
MARKET CAP
2.81B
P/E (TTM)
-94.6669
1D
5D
1M
3M
1Y
5Y
1D
Supernus Pharmaceuticals (SUPN) Gets a Buy from Jefferies
TipRanks · 3d ago
Supernus Pharmaceuticals Price Target Raised to $67.00/Share From $63.00 by Cantor Fitzgerald
Dow Jones · 4d ago
Supernus Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 4d ago
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
NASDAQ · 4d ago
Supernus price target raised to $67 from $63 at Cantor Fitzgerald
TipRanks · 4d ago
Weekly Report: what happened at SUPN last week (0629-0703)?
Weekly Report · 07/06 09:42
Weekly Report: what happened at SUPN last week (0622-0626)?
Weekly Report · 06/29 09:39
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
NASDAQ · 06/26 12:20
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.